Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Treatment of Patients With Newly Diagnosed Type 2 Diabetes: a Multicenter, Randomized Open Trial Study With Parallel Controls

NCT03987308 is registered in ClinicalTrials.gov with Beijing Hospital as lead sponsor.

NCT NCT03987308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03987308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Treatment of Patients With Newly Diagnosed Type 2 Diabetes: a Multicenter, Randomized Open Trial Study With Parallel Controls
Lead sponsor
Beijing Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
July 2, 2019
Completion date
December 31, 2025
Enrollment
115 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

t2dm, t2dm (type 2 diabetes mellitus), type 2 diabetic patients